JP2024524631A5 - - Google Patents
Info
- Publication number
- JP2024524631A5 JP2024524631A5 JP2024501536A JP2024501536A JP2024524631A5 JP 2024524631 A5 JP2024524631 A5 JP 2024524631A5 JP 2024501536 A JP2024501536 A JP 2024501536A JP 2024501536 A JP2024501536 A JP 2024501536A JP 2024524631 A5 JP2024524631 A5 JP 2024524631A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- inhibitors
- interferonism
- lupus erythematosus
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21305971 | 2021-07-12 | ||
| EP21305971.0 | 2021-07-12 | ||
| EP22315039.2 | 2022-02-24 | ||
| EP22315039 | 2022-02-24 | ||
| PCT/EP2022/069362 WO2023285405A1 (en) | 2021-07-12 | 2022-07-11 | Treatment of inflammatory diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024524631A JP2024524631A (ja) | 2024-07-05 |
| JP2024524631A5 true JP2024524631A5 (cg-RX-API-DMAC10.html) | 2025-07-17 |
Family
ID=82748704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024501536A Pending JP2024524631A (ja) | 2021-07-12 | 2022-07-11 | 炎症性疾患の治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240325404A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4370128A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024524631A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20240035480A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2022310901A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3225221A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL309946A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2024000517A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023285405A1 (cg-RX-API-DMAC10.html) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201717260D0 (en) * | 2017-10-20 | 2017-12-06 | Galapagos Nv | Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders |
-
2022
- 2022-07-11 MX MX2024000517A patent/MX2024000517A/es unknown
- 2022-07-11 EP EP22748337.7A patent/EP4370128A1/en active Pending
- 2022-07-11 US US18/578,604 patent/US20240325404A1/en active Pending
- 2022-07-11 KR KR1020247002501A patent/KR20240035480A/ko active Pending
- 2022-07-11 CA CA3225221A patent/CA3225221A1/en active Pending
- 2022-07-11 WO PCT/EP2022/069362 patent/WO2023285405A1/en not_active Ceased
- 2022-07-11 IL IL309946A patent/IL309946A/en unknown
- 2022-07-11 JP JP2024501536A patent/JP2024524631A/ja active Pending
- 2022-07-11 AU AU2022310901A patent/AU2022310901A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022009090A5 (cg-RX-API-DMAC10.html) | ||
| JP6837700B2 (ja) | ジピベフリンの使用方法 | |
| JP5769762B2 (ja) | 治療組成物およびその使用 | |
| JP2023065622A (ja) | 重度腎機能障害を有する癌患者に対する治療方法 | |
| JP6574415B2 (ja) | アタザナビルおよびコビシスタットのhiv治療製剤 | |
| JP5362151B2 (ja) | Pgd2拮抗剤及びヒスタミン拮抗剤からなるアレルギー性鼻炎治療用医薬 | |
| WO2005004915A2 (en) | Compositions comprising meloxicam | |
| US20230115867A1 (en) | Pemafibrate Dosing Regimens | |
| JP2006511538A (ja) | 非ヌクレオシド系逆転写酵素阻害剤(nnrti)とプロテアーゼ阻害剤などのシトクロムp450の阻害剤とを含む組み合わせの使用 | |
| JP6181044B2 (ja) | カプセル剤 | |
| JP2021503457A (ja) | 二元的なmekシグナル伝達の低減によるがん治療 | |
| EP4196116B1 (en) | Pharmaceutical composition comprising cabozantinib, plerixafor, afatinib and etoricoxib for use in the treatment or prophylaxis of nsclc without driver mutations | |
| BR112021012255A2 (pt) | Método para o tratamento de um câncer em um paciente, método para reduzir efeitos colaterais do tratamento de um câncer em um paciente, combinação de um inibidor de cyp3a e docetaxel para uso em um tratamento médico de um câncer, docetaxel para uso em uma terapia de combinação no tratamento de câncer, inibidor de cyp3a para uso em uma terapia de combinação no tratamento de câncer, uso e kit que compreende uma composição farmacêutica para administração oral que compreende docetaxel e uma composição farmacêutica que compreende um inibidor de cyp3a | |
| CN115778956A (zh) | 用于治疗癌症的口服给药紫杉醇和P-gp抑制剂的治疗组合 | |
| GB2597635A (en) | Combinations | |
| EP1667719B1 (en) | Treatment of gastrointestinal stromal tumors with imatinib and midostaurin | |
| RU2842683C1 (ru) | Фармацевтическая комбинация осельтамивира, парацетамола, источника витамина с и блокатора гистаминовых рецепторов | |
| Tablets | Full Prescribing Information | |
| RU2234922C2 (ru) | Антигриппозный комплексный препарат | |
| WO2025265030A1 (en) | Concomitant administration of selective glucocorticoid receptor modulator relacorilant and p-glycoprotein substrates | |
| US20140322320A1 (en) | Novel compositions for emesis control in cancer patients undergoing chemotherapy and methods thereof | |
| RU2543322C1 (ru) | Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения | |
| EP4114366A1 (en) | Pharmaceutical compositions comprising dasatinib anhydrous and uses thereof |